CONGRESS FOR VOTERS

Robert Bresnahan (R-PA)

340B Rebate Model Delay Act

H.R. 10770 · House bill Health

A Republican bill with 23 Democratic cosponsors · See all 28 cosponsors

Last activity — Referred to the House Committee on Energy and Commerce.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

This bill is known as the 340B Rebate Model Delay Act. It temporarily limits the use of rebates under the 340B Program. From January 1, 2027, through December 31, 2028, the Secretary may not enter into agreements where drug payments exceed the ceiling price at the point of purchase for certain entities. Additionally, it prevents the Secretary from implementing the 340B Rebate Model Pilot Program or any substantially similar program during that same time period.

Yes

  • Scored +3

    Does this lower the price of prescription medicines?

    By temporarily limiting rebate models and capping drug prices at the point of purchase for covered entities, the bill helps ensure more affordable access to outpatient drugs.

  • Scored +2

    Would people over 65 be better off under this?

    Maintaining lower upfront costs for outpatient drugs under the 340B program benefits seniors who frequently rely on prescription medications.

  • Scored +2

    Would households on low incomes be better off under this?

    Keeping point-of-purchase prices at or below the ceiling price helps low-income individuals access affordable medications at safety-net providers.

The opposite

No question was scored the opposite.